Trial Profile

Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Jun 2024 Results of the dynamic changes in both the tumor and its microenvironment in response to treatment and mechanisms of acquired resistance using spatial transcriptomics, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
13 Sep 2022 Results assessing diagnostic accuracy of Gene-Protein Assay to find HER2 intratumoral genetic and non-genetic heterogeneity using samples from this trial presented at the 47th European Society for Medical Oncology Congress
27 Jun 2022 Planned End Date changed from 31 Mar 2023 to 30 Apr 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com